Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism
- 1 December 1998
- journal article
- Published by Elsevier BV in American Journal Of Medicine
- Vol. 105 (6), 472-477
- https://doi.org/10.1016/s0002-9343(98)00355-6
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trialJournal of the American College of Cardiology, 1992
- Intracranial hemorrhage in association with thrombolytic therapy: Incidence and clinical predictive factorsJournal of the American College of Cardiology, 1992
- Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: A European multicenter double-blind trialJournal of the American College of Cardiology, 1992
- MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarctionThe Lancet, 1990
- Comparison of perfusion lung scanning and angiography in the estimation of vascular obstruction in acute pulmonary embolismEuropean Journal of Nuclear Medicine and Molecular Imaging, 1990
- RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISMThe Lancet, 1988
- Hemodynamic and ventricular responses to pulmonary embolismProgress in Cardiovascular Diseases, 1974
- Comparison of Streptokinase and Heparin in Treatment of Isolated Acute Massive Pulmonary EmbolismBMJ, 1971
- A Coefficient of Agreement for Nominal ScalesEducational and Psychological Measurement, 1960